This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/JBIO/capital-change-brief"
Use Arkolith's capital_change_brief for JBIO. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | $99.6M | 7.1M | ▲+2.8% Added · +191K sh | Q1 2026 | |
| 2 | Fairmount Funds Management LLC | $64.0M | 4.6M | —Held | Q1 2026 | |
| 3 | RA CAPITAL MANAGEMENT, L.P. | $51.6M | 3.7M | —Held | Q1 2026 | |
| 4 | Bellevue Group AG | $49.2M | 3.5M | ▲+4.8% Added · +160K sh | Q1 2026 | |
| 5 | Venrock Adviser, LLC | $45.2M | 3.2M | —Held | Q1 2026 | |
| 6 | JANUS HENDERSON GROUP PLC | $43.6M | 3.1M | ▲New +3.1M sh | Q1 2026 | |
| 7 | BlackRock, Inc. | $32.5M | 2.3M | ▼−19% Reduced · −556K sh | Q1 2026 | |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | $25.2M | 1.8M | ▲New +1.8M sh | Q1 2026 | |
| 9 | BAKER BROS. ADVISORS LP | $23.1M | 1.6M | —Held | Q1 2026 | |
| 10 | Remedium Capital Partners, LLC | $22.2M | 1.6M | —Held | Q1 2026 | |
| 11 | Avidity Partners Management LP | $19.7M | 1.4M | —Held | Q1 2026 | |
| 12 | Samsara BioCapital, LLC | $13.6M | 969K | —Held | Q1 2026 | |
| 13 | GREAT POINT PARTNERS LLC | $13.6M | 964K | ▲+20% Added · +158K sh | Q1 2026 | |
| 14 | MARSHALL WACE, LLP | $13.3M | 945K | ▲+7.9% Added · +70K sh | Q1 2026 | |
| 15 | Aberdeen Group plc | $12.2M | 867K | —Held | Q1 2026 | |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | $11.6M | 823K | ▼−2.3% Reduced · −19K sh | Q1 2026 | |
| 17 | Soleus Capital Management, L.P. | $11.2M | 797K | —Held | Q1 2026 | |
| 18 | ACORN CAPITAL ADVISORS, LLC | $11.1M | 787K | ▲New +787K sh | Q1 2026 | |
| 19 | STATE STREET CORP | $9.2M | 656K | ▲+2.0% Added · +13K sh | Q1 2026 | |
| 20 | Affinity Asset Advisors, LLC | $9.0M | 640K | ▼−10% Reduced · −75K sh | Q1 2026 | |
| 21 | RTW INVESTMENTS, LP | $8.1M | 573K | ▼−60% Reduced · −876K sh | Q1 2026 | |
| 22 | Ikarian Capital, LLC | $7.2M | 512K | ▲+71% Added · +212K sh | Q1 2026 | |
| 23 | Opaleye Management Inc. | $6.0M | 428K | —Held | Q1 2026 | |
| 24 | BALYASNY ASSET MANAGEMENT L.P. | $5.7M | 402K | ▲New +402K sh | Q1 2026 | |
| 25 | Logos Global Management LP | $5.6M | 400K | ▲+1.3% Added · +5K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jun 25, 2026 | Eisner Mark | Director | Grant (A) | 48K | $0 |
| Jun 9, 2026 | Lavelle Erin | Director | Grant (A) | 35K | $0 |
| Jun 9, 2026 | CAIN CHRISTOPHER W. | Director | Grant (A) | 35K | $0 |
| Jun 9, 2026 | Fairmount Funds Management LLC | Director, 10% Owner | Grant (A) | 35K | $0 |
| Jun 9, 2026 | DOBMEIER ERIC | Director | Grant (A) | 35K | $0 |
| Jun 9, 2026 | Klein Lawrence Otto | Director | Grant (A) | 35K | $0 |
| Feb 12, 2026 | King Andrew James | See Remarks | Grant (A) | 41K | $0 |
| Feb 12, 2026 | King Andrew James | See Remarks | Grant (A) | 248K | $0 |
| Feb 12, 2026 | Frohlich Tom | Chief Executive Officer, Director | Grant (A) | 79K | $0 |
| Feb 12, 2026 | Frohlich Tom | Chief Executive Officer, Director | Grant (A) | 473K | $0 |
| Feb 12, 2026 | Balta Elizabeth | See Remarks | Grant (A) | 28K | $0 |
| Feb 12, 2026 | Balta Elizabeth | See Remarks | Grant (A) | 169K | $0 |
| Company | Co-held by | Combined value |
|---|---|---|
| ORIC PHARMACEUTICALS INCORIC | 28 funds | $151.0M |
| ELI LILLY & COLLY | 27 funds | $2.1B |
| PRAXIS PRECISION MEDICINES IPRAX | 27 funds | $1.0B |
| NATERA INCNTRA | 27 funds | $873.1M |
| COGENT BIOSCIENCES INCCOGT | 27 funds | $525.7M |
| DISC MEDICINE INCIRON | 27 funds | $331.1M |
| NEUROCRINE BIOSCIENCES INCNBIX | 27 funds | $241.5M |
| DYNE THERAPEUTICS INCDYN | 27 funds | $172.5M |
| INTUITIVE SURGICAL INCISRG | 26 funds | $1.6B |
| ACADIA PHARMACEUTICALS INCACAD | 26 funds | $1.2B |
| BOSTON SCIENTIFIC CORPBSX | 26 funds | $1.0B |
| TANGO THERAPEUTICS INCTNGX | 26 funds | $446.4M |
Ranked by how many of JBIO's institutional holders also hold each name, a cross-fund conviction signal. Via the MCP server (ticker.co_held).
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for JBIO. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes. Every panel above is one call to the Arkolith API & MCP server.